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Abstract
Japanese encephalitis is a severe central nervous system (CNS) inflammatory disease caused by the mosquito-borne
flavivirus, Japanese encephalitis virus (JEV). In the current study we have investigated the immune responses against JEV in
mice lacking expression of the chemokine receptor CCR5, which functions in activation and chemotaxis of leukocytes during
infection. We show that CCR5 serves as a host antiviral factor against Japanese encephalitis, with CCR5 deficiency markedly
increasing mortality, and viral burden in the CNS. Humoral immune responses, which are essential in recovery from JEV
infection, were of similar magnitude in CCR5 sufficient and deficient mice. However, absence of CCR5 resulted in a
multifaceted deficiency of cellular immune responses characterized by reduced natural killer and CD8+ T cell activity, low
splenic cellularity, and impaired trafficking of leukocytes to the brain. Interestingly, adoptive transfer of immune spleen cells,
depleted of B lymphocytes, increased resistance of CCR5-deficient recipient mice against JEV regardless of whether the cells
were obtained from CCR5-deficient or wild-type donor mice, and only when transferred at one but not at three days post-
challenge. This result is consistent with a mechanism by which CCR5 expression enhances lymphocyte activation and
thereby promotes host survival in Japanese encephalitis.
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Introduction
The migration of leukocytes in lymphoid organs and to sites of
inflammation is coordinated by an array of chemokines that bind
to specific receptors on immune cells (reviewed in [1]). Of these,
the chemokine receptor, CCR5, is expressed on natural killer (NK)
cells, macrophages, and CD4+ and CD8+ T cells. In these cell
types, it regulates chemotaxis and cell activation through
interaction with the chemokine ligands CCL3, CCL4 and
CCL5, which are up-regulated at the site of infection (reviewed
in [2]). Understanding the role of CCR5 in the control of
pathogen infections has important implications for human health
beyond that of other chemokine ligand/receptor interactions, in
view of the discovery that CCR5 is a major co-receptor for HIV-1
(reviewed in [3]). Therefore, the chemokine receptor is an
important target for therapeutic intervention against HIV/AIDS,
and recent clinical trials investigating the efficacy of CCR5
antagonists in patients with HIV/AIDS have provided promising
results (reviewed in [4]). However, it has been argued that if CCR5
had a protective role against another group of pathogens, for
instance in flaviviral encephalitis, it follows that a therapeutic
treatment, which aims to block the receptor, could exacerbate the
diseases caused by these pathogens [5,6].
CCR5 was the first chemokine receptor recognized to play a
critical role in recovery from flavivirus encephalitis in a study that
showed that absence of CCR5 prevented efficient leukocyte
trafficking to the brain and viral clearance in mice infected with
West Nile virus (WNV) [7]. The important role of CCR5 in the
human host response against West Nile encephalitis was supported
by a retrospective cohort study involving persons homozygous for
CCR5D32 [8], a loss-of-function mutation found in 1–2% of
Caucasians [2]. Compared to individuals without the mutation,
persons carrying a homozygous CCR5D32 allele had an increased
risk for symptomatic WNV infection. This finding was corrobo-
rated with a large-scale database study, which associated
homozygosity for CCR5D32 with an increased risk of early and
late clinical manifestation following WNV infection [9].
CCR5D32 homozygosity has also been associated with severe
tick-borne encephalitis symptoms [10] caused by infection with
tick-borne encephalitis virus, and a severe case of yellow fever
virus-associated viscerotropic disease [11]. Tick-borne encephalitis
and yellow fever viruses are also members of the Flavivirus genus,
raising the question of generality of CCR5 as an important host
factor in recovery from flaviviral infections. Confirmation of a
broader link between CCR5 deficiency and augmented incidence
and severity of flaviviral disease would add to the concern of
potential adverse outcomes associated with CCR5 antagonist use,
in view of the large number of human infections inflicted by the
different pathogenic members of the Flavivirus genus, and their
widespread global distribution (reviewed in [12].
Here we have investigated the role and mechanism of CCR5 in
recovery from infection in a mouse model of Japanese encephalitis.
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Japanese encephalitis virus (JEV) is closely related to WNV, and in
terms of human disease incidence and severity the most important
member of a serocomplex of mosquito-borne, encephalitic
flaviviruses (reviewed in [13]). It is the leading cause of viral
encephalitis in Asia, annually accounting for 30,000 to 50,000
cases and ,10,000 deaths. Approximately 3 billion people in the
Asia-Pacific region are at risk of infection with JEV. Host immune
factors are thought to be the dominant determinants of disease
outcome in Japanese encephalitis (reviewed in [14,15]), with intact
type I interferon and vigorous humoral immune responses
essential for recovery, and CD8+ T cell immunity providing a
subsidiary contribution to controlling JEV infection [16,17]. With
the use of CCR5-deficient mice we show in this study that the
chemokine receptor is an additional important host factor involved
in reducing disease severity with Japanese encephalitis.
Materials and Methods
Ethics statement
All animal experiments were approved by and conducted in
accordance with the Australian National University (ANU) Animal
Ethics Committee.
Virus and cells
African green monkey kidney (Vero) cells were obtained from
the American Type Culture Collection. Working stocks of JEV
(strain Nakayama) were infected Vero cell culture supernatants
(26108 PFU/ml) stored in single-use aliquots at270uC. Vero cells
and YAC-1 cells (Moloney leukemia virus-induced T cell
lymphoma) [18] were grown at 37uC in Eagle’s minimal essential
medium plus nonessential amino acids (MEM) supplemented with
5% fetal bovine serum (FBS). Virus titration was by plaque assay
on Vero cell monolayers, as described previously [19].
Mice
Congenic CCR52/2 mice (B6.129P2-Ccr5tm1Kuz/J) [20] and
their wild-type controls were bred under specific-pathogen-free
conditions and supplied by the Animal Breeding Facility at the
John Curtin School of Medical Research, ANU, Canberra.
Female mice were used in all experiments.
Mouse inoculation and tissue collection
Mice were infected intravenously (i.v.) via the lateral tail vein
with a single injection of 16103 PFU of JEV in 100 ml Hanks’
balanced salt solution containing 20 mM HEPES (pH 8.0) and
0.2% bovine serum albumin (HBSS-BSA). Mice were monitored
twice daily, and changes in 5 parameters including hair coat,
posture, breathing pattern, activity, and movement were scored as
normal (0), mild (1), moderate (2) or severe (3). Severely moribund
mice were euthanized if the overall clinical score was .7, and/or
when hindlimb paralysis was observed. For tissue processing, mice
were euthanized at the time points indicated and a sterile midline
vertical thoracoabdominal incision was made to expose the
internal organs. After cardiac puncture for blood collection,
animals were perfused with 10 ml sterile PBS. The brain and
spinal cord were excised intact and collected for virus titration. For
determination of virus titers, sample tissues were snap-frozen on
dry ice. One-half of the brain samples were placed in cell culture
medium and homogenized for lymphocyte isolation.
Real-time RT-PCR
For determination of viral burden in mouse serum and spleen
samples, total RNA in 50 ml splenic homogenates (10% [wt/vol])
and 50 ml serum was extracted using Trizol as described previously
[21], and virion RNA content, expressed in genome equivalents,
was determined by quantitative reverse transcription (RT)-PCR.
For a genome copy standard, JEV RNA extracted from a Vero
cell-grown virus stock and quantitated by spectrophotometry was
used. RT was performed at 43uC for 90 min in a 10 ml mixture
containing 2 ml sample RNA, Expand reverse transcriptase
(Roche), RNase inhibitor (Invitrogen), 10 mM deoxynucleoside
triphosphate, 10 pmol downstream primer (59-
TTGACCGTTGTTACTGCAAGGC-39), 10 mM dithiothreitol,
and the manufacturer’s recommended buffer condition. Real-time
PCR was performed using IQSybr qPCR mixture (Bio-Rad) and
0.2 nM downstream and upstream primers (59-GCTGGATT-
CAACGAAAGCCACA-39) under cycling conditions of 95uC for
3 min for 1 cycle and 95uC for 30 sec, 63uC for 30 sec and 72uC
for 60 sec for 40 cycles. Each sample was tested in duplicate, and
genome copy numbers were determined by extrapolation from a
standard curve generated within each experiment. The detection
limit of the assay was 46103 RNA copies/ml.
Lymphocyte isolation from brain
Homogenized brain samples were digested with 2 mg/ml
collagenase type I (Gibco-Life Technologies) in MEM plus 5%
FBS for 45 min at 37uC with intermittent shaking and then
centrifuged at 4006 g for 10 min. Pellets were suspended in 2 ml
90% Percoll (GE Healthcare) in MEM plus 5% FBS and overlaid
gently with 60%, 40% and 10% Percoll in MEM plus 5% FBS.
The gradients were centrifuged at 8006g for 45 min at 25uC, and
lymphocytes collected from the 40 to 60% interface were
subsequently analyzed by flow-cytometry.
Cell surface and intracellular cytokine staining
The surface marker staining employed in this study utilized the
following reagents (all from Becton Dickinson except otherwise
indicated): allophycocyanin (APC)-conjugated anti-CD8 antibody;
phycoerythrin (PE)-conjugated anti-CD3, anti-NK1.1, anti-F4/80
(Caltag) and anti-CCR5 antibodies; fluorescein isothiocyanate
(FITC)-conjugated anti-CD4, anti-NK1.1, anti-F4/80 (Serotec)
and anti-CD19 antibodies; and peridinin-chlorophyll-protein
complex (PerCP)-conjugated anti-CD3 antibody (BioLegend).
105 events were acquired for each sample on a four-color
FACSort flow-cytometer. Results were analyzed using Cell Quest
Pro Software. For intracellular cytokine staining, 16106 spleno-
cytes were suspended in 100 ml MEM with 5% FBS and
stimulated for 16 h with 1024 M H-2Db-binding 9-mer JEV
NS4B protein-derived peptide, SAVWNSTTA [16], in the
presence of 1 ml/ml brefeldin A (eBioscience). An ectromelia virus
(ECTV) H-2Kb-restricted peptide, TSYKFESV [22], was used at
1024 M as a negative-control peptide. For stimulation of ex vivo
splenocytes with JEV, splenocytes were infected at a multiplicity of
infection (moi) of 1 for 1 h at 37uC and washed twice with MEM
containing 5% FBS before incubation for 16 h in MEM plus 5%
FBS in the presence of brefeldin A. Enumeration of activated NK
cells by intracellular staining for IFN-c expression was performed
directly on ex vivo splenocytes. Cells were surface stained with
anti-CD8–APC or anti-NK1.1-PE antibodies before paraformal-
dehyde fixation and permeabilization with saponin (Biosource)
according to the supplier’s instruction. Cells were then stained
with anti-IFN-c–FITC (BioLegend) and/or anti-tumor necrosis
factor alpha (TNF-a)–PE (Invitrogen), and washed twice with
fluorescence-activated cell sorter (FACS) washing buffer (2% FBS
in PBS) before assessment by FACS analysis.
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NK cell cytotoxic assay
Mice were infected with 103 PFU of JEV, i.v., and sacrificed at
days 4 and 7 post-infection (pi). Spleens were collected and tested
for NK cell cytotoxicity in a standard 51Cr-release assay [23],
using uninfected YAC-1 cells as targets. Splenocytes from
uninfected mice were used as controls. P values were calculated
from a four-point logarithmic regression curve, interpolated at an
effector-to-target (e/t) cell ratio of 30.
Transfer experiments
Eight-week-old CCR52/2 or CCR5+/+ mice were infected with
16103 PFU of JEV, i.v., and sacrificed a week later for aseptic
removal of spleens. Single-cell splenocyte suspensions were
prepared by pressing the spleen tissue gently through a fine metal
mesh tissue sieve. Erythrocyte lysis was by suspension of the
splenocyte pellet in 4.5 ml distilled water, followed immediately by
the addition of 0.5 ml of 106PBS. Lysed cells were discarded after
centrifugation at 4006g for 5 min. Splenocytes were resuspended
in 100 ml PBS and injected through the lateral tail vein into 8-
week-old CCR52/2 recipient mice. Recipient mice were chal-
lenged one or three days later with 16103 PFU JEV via footpad
injection. For B cell depletion, splenocytes were incubated with
anti-CD19 magnetic beads (Miltenyi Biotec) and loaded onto
magnetic columns according to the supplier’s instructions. Effluent
from the columns was collected, and cells were pelleted by
centrifugation at 4006g for 5 min. The efficiency of B cell
depletion was 99% as assessed by FACS analysis.
Serological tests
For titration of JEV-specific antibody isotypes in mouse serum,
ELISAs were performed with HRP-conjugated rabbit anti-mouse
IgM, IgG1 and IgG2b (Serotec), and the peroxidase substrate 2,29-
azino-di(3-ethyl-benzthiazoline sulfonate). The JEV Nakayama
strain was used for ELISA antigen production as described
previously for Murray Valley encephalitis virus [24]. For
determination of ELISA endpoint titers, absorbance cut-off values
were established as the mean absorbance of eight negative-control
wells containing sera of naive mice plus 3 standard deviations (SD).
Absorbance values of test sera were considered positive if they
were equal to or greater than the absorbance cut-off, and endpoint
titers were calculated as the reciprocal of the last dilution giving a
positive absorbance value. Neutralization titers, measured in a
50% plaque reduction neutralization test (PRNT50), were deter-
mined as previously described [25].
Results
CCR5 is required for protection from Japanese
encephalitis
To assess the impact of CCR5 on the pathogenesis of Japanese
encephalitis, mortality was recorded in 8-week-old congenic
CCR52/2 and CCR5+/+ wild-type mice after i.v. challenge with
103 PFU of JEV. Moribund mice in both groups presented with
similar clinical signs starting with generalized piloerection, paresis
and rigidity, invariably progressing to severe neurological signs
demonstrated by postural imbalance, ataxia and generalized tonic-
clonic seizures. Median survival time amongst mice that
succumbed to infection did not differ between the two groups
(11.762.3 days for CCR52/2 and 11.162.1 days for CCR5+/+
mice). Nevertheless, absence of CCR5 resulted in a significant
increase in mortality: 64% in CCR52/2 versus 28% in CCR5+/+
mice (Figure 1).
To address the mechanism for increased susceptibility of mice to
JEV infection in the absence of CCR5, viral titers in CCR52/2
and control mice infected with 103 PFU, i.v., were determined by
real-time RT-PCR in serum and spleen, and by plaque assay in
brain and spinal cord. Both groups displayed similar viral burden
in serum from day 2 to day 6 pi, with peak viremia occurring on
day 2 pi (Figure 2A). Similarly, viral load in spleen did not differ
significantly between the two groups (Figure 2B). On the other
hand, viral spread into and/or clearance from the CNS was
significantly affected by the absence of CCR5: compared to
control mice, viral load in brains of CCR52/2 mice was between
10- and 10,000-fold higher on days 8 and 10 pi, respectively, with
the proportion of mice showing detectable virus titers markedly
greater in CCR52/2 mice than that in the control group
(Figure 2C). In addition, viral spread in the CNS was more
pronounced in CCR52/2 mice, with viral titers in spinal cord
exceeding those in CCR5+/+ mice by four log on day 10 pi
(Figure 2D).
Together, these data suggest that CCR5 is critically required for
recovery from JEV infection.
Humoral immunity in the absence of CCR5
We have previously established a pivotal role of antibody in
recovery from JEV infection [16]. Given that CCR5 is expressed
on CD4+ T cells, which are required for efficient generation and
maintenance of humoral immunity against JEV, we investigated
whether a deficiency in CCR5 would result in poorer JEV-specific
antibody responses. However, the kinetics and magnitude of the
IgM response was similar in CCR52/2 and control mice,
appearing first on day 4 pi, and peaking on day 8 pi
(Figure 3A). Class switching to IgG production was also
comparable between both groups, initially detected on day 8 pi,
and increasing on day 10 pi (Figure 3B). Assessment of functional
activity of the antibody responses by neutralization assay revealed
no significant difference between the two groups, reaching mean
PRNT50 titers of 660 (range, 80 to 1280) in CCR5
2/2 mice and
570 (range, 160 to 1280) in CCR5+/+ mice on day 10 pi
(Figure 3C).
These data indicate that a deficiency in CCR5 does not
compromise the ability of mice to prime JEV-specific B cell
immune responses.
Blunted NK and CD8+ T cell responses in CCR52/2 mice
NK cells form an important part of the cellular arm of the host’s
innate immunity, and function by killing virally infected cells and
by release of the cytokines, IFN-c and TNF-a. NK cell activity in
JEV infected CCR52/2 and control mice were determined by
Figure 1. Susceptibility of CCR5+/+ and CCR52/2 mice to
infection with JEV. Groups of 8-week-old mice were infected i.v.
with 103 PFU of JEV. Morbidity and mortality were recorded daily, and
surviving mice were monitored for 28 days. The data shown were
constructed from two independent experiments. The significance of
differences in mortality between wild-type (n = 28) and knockout mice
(n = 42) was determined by using the log-rank test (**, P,0.01).
doi:10.1371/journal.pone.0044834.g001
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measuring cytolytic activity against YAC-1 cells and by intracel-
lular staining of IFN-c. At the peak of NK cell activity (day 4 pi),
lysis of YAC-1 cells was significantly reduced in CCR52/2 mice
compared to CCR5+/+ mice (Figure 4A and 4B). This was
substantiated by a significantly reduced number of activated, IFN-
c-expressing, NK cells in spleen of CCR52/2 relative to control
mice at day 4 pi (Figure 4C).
CD8+ T cells form the dominant cytotoxic arm of the adaptive
immune system. We previously reported a subsidiary role of CD8+
T cells in recovery from JEV infection [16], and hypothesized that
a defective CD8+ T cell response could, at least in part, account for
the increase in susceptibility of CCR52/2 mice to JEV infection.
The primary murine CD8+ T cell responses against JEV and other
flaviviruses peak at 7 days pi, and thereafter markedly decline
[16,26,27]. Figure 4D demonstrates a significantly blunted JEV-
immune CD8+ T cell response in CCR52/2 relative to control
mice, determined by intracellular cytokine staining following ex
vivo stimulation of CD8+ lymphocytes with a JEV NS4B protein-
derived H-2Db-binding peptide. Relative to CCR5+/+ mice,
CCR52/2 mice showed a 61% and 74% reduction in the number
of IFN-c-secreting CD8+ T cells, and a 60% and 64% reduction in
the number of TNF-a-secreting CD8+ T cells in spleen on days 4
and 7 pi with JEV, respectively (Figure 4E). This was also
reflected in a significantly smaller number of dual-functional JEV-
immune CD8+ T cells (defined as the number of CD8+ T cells
expressing both IFN-c and TNF-a following stimulation with
cognate peptide), which was reduced by 3-fold and 4-fold on days
4 and 7 pi, respectively, in the absence of CCR5 expression
(Figure 4F).
Collectively, these data indicate that a deficiency in CCR5
results in blunted NK and CD8+ T cell responses after JEV
infection.
Impaired leukocyte proliferation and trafficking in
CCR52/2 mice
CCR5 expression drives the migration of leukocytes into the
CNS after WNV infection, and thereby contributes to viral
clearance and recovery from infection [7]. To investigate whether
this is also evident in our mouse model of Japanese encephalitis,
we isolated leukocytes from brains of JEV infected CCR5+/+ and
CCR52/2 mice by density gradient centrifugation and quantified
leukocyte subpopulations by flow-cytometry. On day 7 pi,
CCR52/2 mice showed a significant (,50%) reduction in
infiltration of leukocytes into the brain relative to control mice,
and this effect was found for all CCR5-expressing subpopulations,
viz. NK cells, F480+/CD45hi macrophages, CD8+ T cells and
CD4+ T cells (Figure 5A–D). This difference ceased to be
significant by day 10 pi. These data show that in the case of
Japanese encephalitis, the absence of CCR5 resulted in delayed
trafficking of leukocytes into the brain, despite the much higher
virus titers in the CNS of infected CCR52/2 than CCR5+/+ mice.
Given the role of CCR5 expression in augmented leukocyte
trafficking into the brain, we next assessed the proportion of cells
of the different leukocyte subpopulations that express the
chemokine receptor using CCR5+/+ mice that were infected with
JEV. On day 7 pi, 15% of NK cells, 12% of F4/80+/CD45hi
infiltrating macrophages, 8% of CD8+ T cells and 20% of CD4+ T
cells were CCR5-positive (Figure 5E). This proportion increased
Figure 2. JEV burden in serum and tissue samples. JEV burden in (A) serum, (B) spleen, (C) brain and (D) spinal cord of CCR5+/+ and CCR52/2
mice after i.v. infection with 103 PFU of JEV. At the indicated time points, animals were sacrificed and the viral RNA content of serum and spleen
samples were measured by real-time RT-PCR, while viral content in brain and spinal cord samples were measured by plaque titration. Data shown
were constructed from 2 independent experiments. Each symbol represents an individual mouse, and geometric mean titers are indicated by
horizontal lines. The lower limit of virus detection is indicated by the horizontal dotted line. Asterisks denote significant differences (**, P,0.01).
doi:10.1371/journal.pone.0044834.g002
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on day 10 pi in the case of CD8+ T cells (19%) and F4/80+/
CD45hi infiltrating macrophages (16%), but decreased for NK and
CD4+ T cells. Similar numbers of infiltrating CCR5-positive cells
as a proportion of the different leukocyte subpopulations in the
brain have been observed in mice with West Nile encephalitis [7].
To assess whether impaired trafficking of leukocytes, per se, or a
failure of leukocyte expansion in the periphery accounted for the
reduced numbers of immune cells in the brain of infected CCR52/2
relative to control mice, we quantified splenic cellularity in CCR52/2
and CCR5+/+ mice at various time points after JEV infection. As
expected, given that spleen serves as the main immune-responsive
lymphoid organ after an i.v. challenge, total splenocyte numbers in
CCR5+/+ mice increased following infection with JEV, with the peak
expansion on day 7 pi (86107 cells/spleen; Figure 6A). This
contrasted with a significantly lesser number of splenocytes in JEV
infected mice lacking CCR5 expression, although the kinetics of the
response was similar between the two groups of mice (Figure 6A).
The deficit in cell numbers was found across the different CCR5-
encoding splenocyte subpopulations, showing a reduction of 43% for
NK cells, 33% for F4/80+ macrophages, 34% for CD4+ T cells, and
39% for CD8+ T cells in CCR52/2 mice relative to control animals
on day 7 pi (Figure 6B–E). The percentage reduction of T cell
numbers and activation phenotype (Figure 4) in spleen on day 7 pi
correlated closely with the differential leukocyte migration into the
brains of CCR52/2 and wt mice (Figure 5).
Together these data imply that the impaired trafficking of
leukocytes into the CNS after JEV infection in CCR52/2 mice
may, at least in part, be a direct result of a deficit in leukocyte
numbers in the periphery.
Early transfer of CCR5-deficient splenocytes increases
survival of recipient CCR52/2 mice challenged with JEV
Our mechanistic studies on the role of CCR5 in recovery from
JEV infection showed deficiencies in leukocyte trafficking to the
CNS, blunted NK and CD8+ T cell responses, and low splenic
cellularity, while a previous investigation on WNV concluded that
CCR5 increased host survival predominantly by promoting
leukocyte migration to the infected brain [7]. To test whether
defective immune cell priming and expansion significantly
contributed to the increased susceptibility of CCR52/2 mice to
JEV infection, we adoptively transferred splenocytes from JEV
infected CCR52/2 and CCR5+/+ mice to CCR52/2 recipients
lethally challenged with the virus. Complete protection was
achieved when total immune splenocytes from either donor strain
were transferred at day 1 pi with JEV (Table 1). In contrast, no
increase in survival was observed when the transfers were
performed at 3 days pi, independent of whether the donor mice
were CCR5 sufficient or deficient. This suggested that following
the establishment of a CNS infection, viral clearance and
protection mediated by the adaptive immune responses is
ineffective in the case of Japanese encephalitis. This conclusion
is not limited to the CCR5-deficient recipient mice, since a similar
lack of protective value against JEV of late transfer (day 3 post-
challenge) of immune spleen cells was also found in wild-type B6
recipients (unpublished data).
Given the dominant role of B cells (which do not express CCR5)
in recovery from Japanese encephalitis [16], we next performed
adoptive transfer experiments of B cell-depleted splenocytes from
CCR52/2 and CCR5+/+ donor mice to CCR52/2 recipients at
one day after JEV infection. Interestingly, even B cell-depleted
splenocytes from both donor mice provided significant, albeit not
complete, protection, increasing the survival rate of recipient mice
to that of untreated CCR5+/+ mice infected with JEV (Table 1).
Together, these data confirm the important role of B cells in
protection against Japanese encephalitis, and indicate that CCR5
expression was not required for the disease-ameliorating effect of B
cell-depleted lymphocytes primed against JEV. The data also
suggest that in adoptive transfer of immune T cells control of JEV
infection likely occurred extraneurally, since protection was seen
only when the cells were provided early pi, and that accordingly
migration of the lymphocytes to peripheral sites of infection did
not require expression of CCR5.
Discussion
The role of the chemokine receptor CCR5 in infection is
variable in terms of its impact on pathogenesis and disease
outcome. An important disease-ameliorating contribution of
CCR5 has been documented in settings of trypanosomiasis [28],
toxoplasmosis [29], influenza [30,31], parainfluenza [32], West
Figure 3. Antibody responses in CCR5+/+ and CCR52/2 mice.
Eight-week-old CCR5+/+ and CCR52/2 mice were infected i.v. with
103 PFU of JEV, and serum samples were collected at the indicated time
points. Anti-JEV IgM (A) and IgG (B) isotype antibody titers were
determined by ELISA. The data presented are reciprocal mean endpoint
titers representative of 4 mice per time point with the SEM indicated by
error bars. (C) Neutralizing antibody titers determined by plaque
reduction neutralization assay. The data presented are mean PRNT50
titers representative of 5 mice per time point, and error bars indicate
the SEM.
doi:10.1371/journal.pone.0044834.g003
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Nile encephalitis [7], tick-borne encephalitis [10], genital herpes
[33], and chlamydia infection [34], while no significant effect of
CCR5 deficiency on the outcome of other microbial infections
could be found [35–39]. Mechanistically, the protective value of
CCR5 has been largely attributed to its regulatory effect on
leukocyte trafficking to the site of infection, although additional
functions of CCR5 in the immune response involving antigen
recognition [36,40,41], priming and proliferation of lymphocytes
Figure 4. NK and CD8+ T cell responses in CCR5+/+ and CCR52/2 mice infected with JEV. Eight-week-old CCR5+/+ and CCR52/2 mice were
infected i.v. with 103 PFU of JEV or left uninfected. (A) Spleens were collected at day 4 pi and tested for NK cell cytotoxicity in a standard 51Cr release
assay using uninfected YAC-1 cells as targets. The percentage of NK cell lysis is plotted against an increasing e/t cell ratio. Means for 5 samples6 SEM
are presented, and data are representative of 2 independent experiments. (B) NK cell cytotoxicity at indicated time points with an e/t cell ratio of
120:1. Means for 5 samples 6 the SEM are presented, and data are representative of 2 independent experiments. (C) Numbers of NK1.1+ stained
splenocytes expressing IFN-c were identified by flow cytometry at day 0 and 4 p.i. Means for 5 samples 6 the SEM are presented, and data are
representative of 2 independent experiments. (D) Splenocytes harvested at day 7 p.i. and stimulated ex vivo with live JEV, H-2Db-restricted JEV NS4B
protein-derived peptides, H-2Db-restricted ECTV negative-control peptide or mock treated, and IFN-c production in CD8+ T cells was measured by
flow cytometry. Means for 3 samples6 the SEM are presented, and data are representative of 2 independent experiments. (E) Kinetics of JEV immune
CD8+ T cell activation measured after ex vivo stimulation with Db-restricted JEV NS4B peptide, showing percentage of CD8+ T cells per spleen that
express IFN-c, TNF-a, or (F) both cytokines following stimulation. Asterisks denote significant differences (*, P,0.05).
doi:10.1371/journal.pone.0044834.g004
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[33,36,37,40–44], and T cell memory formation [32,45] have also
been recognized. In contrast, a disease-potentiating effect of
CCR5 has been found in experimental cerebral malaria [46],
schistosomiasis [47], leishmaniasis [48], cryptococcosis [49],
herpes keratitis [50], mouse hepatitis virus-induced multiple
sclerosis [51], and HIV/AIDS [52], mostly as a consequence of
increased immunopathology, and in the case of HIV/AIDS due to
usage of CCR5 as an alternative receptor for virus infection
(reviewed in [3]). This dichotomy in the role of CCR5 in the
immune response to infection with different pathogens prevents
generalization of the impact of the chemokine receptor in disease
prognosis.
In the present study we establish a critical role of CCR5 in
recovery from Japanese encephalitis, which was reflected in
increased viral burden in the CNS, but not extraneural tissues, and
increased mortality in the absence of CCR5 expression. It was
previously shown that type I interferon and antibody, but not T
cells, are key to control of virus replication in peripheral tissues in
the mouse model of Japanese encephalitis, while T cells play a role
in reducing viral burden and dissemination in the CNS [16].
CCR5-deficient mice displayed a wide-ranging debilitation of
JEV-specific immune responses; these included poor NK cell
activity, a suboptimal JEV-immune CD8+ T cell response, low
splenic cellularity, and impaired trafficking of leukocytes (NK cells,
macrophages, and CD8+ and CD4+ T cells) to the brain. These
factors most likely acted in concert to create a lethal combination
of defective viral clearance from peripheral tissues and the CNS,
thereby increasing the susceptibility of the host to JEV infection. In
addition, recent findings suggest that CCR5, which is expressed in
neurons and is up-regulated in the brain in pathological
conditions, could have a direct neuro-protective function by
increasing neuronal survival (reviewed in [2]).
Figure 5. Leukocyte trafficking into the CNS. Kinetics of cell infiltration into the brain of 8-week-old CCR5+/+ and CCR52/2 mice infected i.v. with
103 PFU of JEV. Leukocytes were isolated at indicated time points from the brains of infected mice and stained for identification as (A) CD8+ T cell, (B)
CD4+ T cell, (C) NK1.1+ cell and (D) F4/80+/CD45Hi infiltrating macrophages. (E) Leukocyte subpopulations were gated for CCR5 expression;
histograms show CCR5 expression on brain-derived leukocyte subpopulations on day 10 pi (shaded histograms). Means are derived from 4–9
samples per time point, error bars denote the SEM, and data are representative of 2 independent experiments. Asterisks denote significant
differences (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0044834.g005
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Our results are consistent with the previous finding of increased
susceptibility of CCR5-deficient mice in a model of West Nile
encephalitis [7], although mechanistic differences in the role of
CCR5 in recovery from WNV and JEV infection are apparent.
While a significant ($50%) overall reduction in migration of NK
cells, CD4+ and CD8+ T cells, and activated infiltrating
macrophages to the brain of JEV and WNV infected CCR52/2
mice was seen in both investigations, this difference relative to
CCR5+/+ control mice narrowed between days 7 and 10 pi in the
case of JEV infection, but became more pronounced for WNV.
More importantly, the WNV study found similar splenic immune
responses in CCR5 sufficient and deficient mice, whereas we
observed markedly reduced numbers of lymphocytes in spleens of
mice lacking CCR5 expression. It is likely that the latter was a
major factor contributing to the severe phenotype in JEV infected
CCR5-deficient mice, since adoptive transfer of B cell-depleted
immune splenocytes corrected the phenotype, independent of
whether the cells were derived from CCR52/2 or CCR5+/+ donor
mice. Low splenocyte numbers in the absence of CCR5 may
reflect restricted leukocyte proliferation secondary to poor early
priming, increased cell turnover to other lymphoid organs, and/or
increased T cell death. However, since the spleen is the main
responsive peripheral lymphoid organ following an i.v. challenge,
defective proliferation most likely accounts for the diminished
splenocyte numbers in CCR52/2 mice. Moreover, other studies
have also observed restricted proliferation of splenocytes, or
specific subsets thereof, in the absence of CCR5, both in
physiologic [53] and pathologic conditions [33,36]. The latter
studies deal with virus challenge models with a resultant
impairment in control of infection.
Concomitant with the limited number of leukocytes in spleens of
CCR5-deficient mice infected with JEV, the functional activities of
NK and CD8+ T cell responses were blunted, while the antibody
response against JEV did not significantly differ from that elicited
in infected wild-type mice. This finding was consistent with several
other studies that demonstrated a critical role of CCR5 expression
on naı¨ve T cells in activation of CD8+ T cell responses by guiding
the cells to and enhancing interaction with antigen-presenting
dendritic cells in immunogen-draining lymph nodes [40–44]. We
have previously found that co-transfer of immune CD4+ and
CD8+ T cells, but not individual transfer of either lymphocyte
subpopulations, was protective in lethal infection with JEV [16].
Figure 6. Leukocyte numbers in spleen after JEV infection. Kinetics of cell expansion in spleens of 8-week-old CCR5+/+ and CCR52/2 mice
infected i.v. with 103 PFU of JEV. (A) Spleens were collected at indicated time points from infected mice and total splenocyte numbers were
determined. Cells were then stained and identified as CD8+ T cell (B), CD4+ T cell (C), NK1.1+ cell (D) and F4/80+ macrophages (E). Means are derived
from 4–8 samples per time point, error bars denote the SEM, and data are representative of 2 independent experiments. Asterisks denote significant
differences (*, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0044834.g006
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Thus, the suboptimal stimulation of virus-specific T cell responses
together with their reduced migration into the CNS most likely
accounted for the increased susceptibility of CCR5-deficient mice
to Japanese encephalitis.
It is unclear whether the reduced NK cell activity in CCR5-
deficient relative to wild-type mice contributed to the increased
disease severity with Japanese encephalitis, as has been proposed
in studies on herpes simplex virus in CCR52/2 mice [33,36].
Flaviviruses are in general poor inducers of NK cells, and flavivirus
infection reduces the susceptibility of target cells to NK cell lysis
[23,54]. The latter is thought to be a consequence of virus-induced
up-regulation of MHC-I on the surface of flavivirus-infected cells
[55–58]. Therefore, it appears that NK cell responses do not
markedly enhance recovery from flavivirus infection. Consistent
with this interpretation, in vivo depletion of NK cells using
monoclonal antibody anti-NK1.1 did not result in increased
mortality or increased viral burden in the CNS in adult mice
infected with JEV (our unpublished result) or WNV [59].
In conclusion, our study established CCR5 as a host factor
against severe disease in a mouse model of Japanese encephalitis.
Control and elimination of viral spread is largely dependent on
rapid activation of antiviral leukocytes, and their recruitment to
the sites of peripheral infection and/or into the CNS. In the
absence of CCR5, an extensive immune dysfunction ensued,
encompassing probable involvement of defective early priming
and subsequent aberrant leukocyte activation, restricted splenocyte
expansion, and limited trafficking. This finding raises possible
safety concerns regarding the use of CCR5 antagonists in HIV
individuals, particularly in regions where both HIV and JEV are
endemic [60,61]. While the benefits of taking the drug most likely
far outweigh the potential risk of enhanced susceptibility to
Japanese encephalitis, mitigating the latter risk factor by instituting
precautionary measures including patient education, limiting
mosquito exposure, and/or vaccination may be warranted.
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